BTIG Reiterates Buy Rating for Gain Therapeutics, Inc. (GANX)
BTIG maintains its buy rating on Gain Therapeutics, Inc. with a $5 price target, a 146.31% upside from the current price.
Key Points
- BTIG reiterated its buy rating for Gain Therapeutics, Inc. (GANX) with a $5 price target on June 30, 2026.
- BTIG's $5 price target implies 146.31% upside from Gain Therapeutics, Inc.'s ($GANX) current $2.03 share price.
- Shares of Gain Therapeutics, Inc. traded at $2.03 on Wednesday, with a market cap of approximately $86.6 million.
- Insiders, including CEO Gene Mack, have recently been buying shares; analysts maintain a consensus buy rating.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
BTIG has reiterated its buy rating on Gain Therapeutics, Inc. (NASDAQ:GANX), setting a price target of $5. This announcement came on June 30, 2026, with analyst Thomas Shrader maintaining the positive outlook on the biotechnology company.
BTIG vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Other Institutional Activity in Gain Therapeutics
Marshall Wace, LLP increased its stake in Gain Therapeutics by 107,495 shares, finishing the period with 1,769,788 shares valued at about $3.43 million, a 6.5% increase. Potomac Capital Management, Inc. slightly reduced its holdings by 1,400 shares, ending with 1,008,600 shares worth approximately $1.96 million, a 0.1% decrease. Jones Financial Companies LLLP cut its position by 70,598 shares, resulting in 631,615 shares valued at $1.16 million, a 10.1% decrease. Meanwhile, Geode Capital Management, LLC added 49,400 shares, bringing its total to 447,342 shares, valued at about $868,527, marking a 12.4% increase.
Gain Therapeutics, Inc. Stock Up 14.7%
Shares of NasdaqGM:GANX traded near $2.03 on Wednesday. Gain Therapeutics has a market cap of about $86.6 million and a beta of 0.164, indicating low volatility. The stock's 52-week range is between $1.41 and $4.34, with a 50-day moving average of $1.83 and a 200-day moving average of $2.20. The company has a strong liquidity position, with a current ratio of 4.688 and a quick ratio of 4.511. However, it is not currently profitable, as indicated by its negative forward P/E ratio.
$GANX price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Insider Buying and Selling at Gain Therapeutics, Inc.
Several insiders have been buying shares of Gain Therapeutics. On March 24, 2026, CEO Gene Mack purchased 200,000 shares. Gianluca Fuggetta also acquired 50,000 shares on the same day. Earlier, on June 24, 2025, insiders Jeffrey Scott Riley, Eric Richman, Claude Nicaise, and Khalid Islam each bought 15,000 shares.
Analysts Set New Price Targets
On June 30, 2026, BTIG maintained its buy rating on Gain Therapeutics with a $5 price target. Previously, HC Wainwright & Co. reiterated a buy rating with an $8 target on October 13, 2025. Maxim Group also maintained a buy rating with a $7 target on October 7, 2025. The consensus among analysts is a buy rating, with an average price target of $7.2 based on five opinions.
About Gain Therapeutics, Inc.
Gain Therapeutics, Inc. is a biotechnology firm based in Bethesda, Maryland. The company focuses on developing small molecule therapeutics to treat various diseases, including Parkinson's and Alzheimer's. Its Magellan platform aids in discovering new binding sites for drug development. Gain Therapeutics' lead drug candidate, GT-02287, is in a Phase 1b trial for Parkinson's disease. Founded in 2017, the company operates in multiple countries, including the United States and Australia.
Bottom Line
BTIG's reiteration of a buy rating on Gain Therapeutics, Inc. reflects continued confidence in the company's prospects. With a focus on innovative therapeutics, the firm remains an interesting player in the biotech sector. Investors should note that analyst ratings are based on past data and may not reflect current market conditions.
Get Gain Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $GANX, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.